Slabilen, 5 mg 10 pcs.

Pharmacotherapeutic group: Laxative

ATC code: A06AB08

Pharmacodynamics:

Sodium picosulfate is a laxative. It is hydrolyzed under the influence of intestinal microorganisms with the formation of active form which causes excitation of mucous membrane receptors of the large intestine and intensification of its peristalsis. The action comes within 10-12 hours after intake.

Pharmacokinetics:

After oral administration it is not absorbed from the gastrointestinal tract and is not subjected to hepatic circulation.

Indications

Slabilen can be used in the following cases:

constipation caused by atony and hypotension of the colon

(that is, a decrease in the activity of colon peristalsis, including in old age, in bedridden patients, after operations, after childbirth, during breastfeeding);

constipation caused by taking medications;

to regulate stool in case of hemorrhoids, proctitis, anal fissures (to soften the consistency of stool);

gallbladder diseases, irritable bowel syndrome with a predominance of constipation;

constipation caused by intestinal dysbiosis, poor diet.

Pharmacological effect

Pharmacotherapeutic group: Laxative

ATX code: A06AB08

Pharmacodynamics:

Sodium picosulfate is a laxative. Under the influence of intestinal microorganisms, it is hydrolyzed to form an active form, which causes stimulation of the receptors of the mucous membrane of the large intestine and increased peristalsis. The effect occurs 10-12 hours after administration.

Pharmacokinetics:

After oral administration, it is not absorbed from the gastrointestinal tract and does not undergo hepatic-intestinal circulation.

Special instructions

Should not be used daily without medical supervision for more than 10 days. In children it should be used only as prescribed by a doctor.

Impact on the ability to drive vehicles. Wed and fur.:

Sodium picosulfate does not affect the ability to drive vehicles and perform work requiring high speed psychomotor reactions.

Active ingredient

Sodium picosulfate

Composition

1 tablet contains:

Active substance:

sodium picosulfate in terms of anhydrous substance 5 mg.

Excipients: Potato starch 27.64 mg, lactose monohydrate (milk sugar) 58.45 mg, povidone (polyvinylpyrrolidone) 2.96 mg, magnesium stearate] 0.95 mg, Opadry II yellow shell [polyvinyl alcohol, talc, macrogol (polyethylene glycol 3350), titanium dioxide, iron oxide yellow dye.

Pregnancy

There are no reliable and well-controlled studies in pregnant women. Long-term experience with use has not revealed a negative effect of sodium picosulfate on pregnancy. The use of sodium picosulfate in the first trimester of pregnancy is contraindicated. In the second and third trimesters of pregnancy (as with the use of other laxatives), the use of the drug is possible only as prescribed by a doctor.

The active metabolite and its glucuronides are not excreted in breast milk. Thus, the drug can be used during breastfeeding.

Contraindications

Hypersensitivity to any of the components of the drug; lactase deficiency lactose intolerance glucose-galactose malabsorption; intestinal obstruction; strangulated hernia; acute inflammatory diseases of the abdominal organs; peritonitis; abdominal pain (of unknown origin); bleeding from the gastrointestinal tract; metrorrhagia; cystitis; severe dehydration; spastic constipation; children under 10 years of age (for this dosage form, children under 10 years of age are recommended to take Slabilen in another dosage form – drops for oral administration); pregnancy (first trimester).

With caution:
II and III trimesters of pregnancy, lactation period.

Side Effects

Diarrhea, abdominal pain, dehydration, water-electrolyte imbalance, weakness, cramps, decreased blood pressure.

Interaction

Possible increased sensitivity to cardiac glycosides. Glucocorticosteroids and diuretics increase the risk of developing electrolyte disturbances.

Broad-spectrum antimicrobials reduce the effectiveness of sodium picosulfate.

Overdose

Symptoms: diarrhea, dehydration, decreased blood pressure, water-electrolyte imbalance, seizures. In addition, with chronic overdose, the development of ischemia of the colon mucosa, secondary hyperaldosteronism, urolithiasis, and damage to the renal tubules is possible.

Treatment: gastric lavage, correction of water-electrolyte imbalance, antispasmodics.

Storage conditions

At a temperature not higher than 25°C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after expiration date.

Manufacturer

Veropharm LLC, Russia